These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

508 related articles for article (PubMed ID: 24713242)

  • 21. MYC/BCL6 double-hit lymphoma (DHL): a tumour associated with an aggressive clinical course and poor prognosis.
    Li S; Desai P; Lin P; Yin CC; Tang G; Wang XJ; Konoplev SN; Khoury JD; Bueso-Ramos CE; Medeiros LJ
    Histopathology; 2016 Jun; 68(7):1090-8. PubMed ID: 26426741
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular classification of MYC-driven B-cell lymphomas by targeted gene expression profiling of fixed biopsy specimens.
    Carey CD; Gusenleitner D; Chapuy B; Kovach AE; Kluk MJ; Sun HH; Crossland RE; Bacon CM; Rand V; Dal Cin P; Le LP; Neuberg D; Sohani AR; Shipp MA; Monti S; Rodig SJ
    J Mol Diagn; 2015 Jan; 17(1):19-30. PubMed ID: 25468432
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type.
    Yoon SO; Jeon YK; Paik JH; Kim WY; Kim YA; Kim JE; Kim CW
    Histopathology; 2008 Aug; 53(2):205-17. PubMed ID: 18752503
    [TBL] [Abstract][Full Text] [Related]  

  • 24. C-MYC and BCL2 translocation frequency in diffuse large B-cell lymphomas: A study of 97 patients.
    Akkaya B; Salim O; Akkaya H; Ozcan M; Yucel OK; Erdem R; Iltar U; Undar L
    Indian J Pathol Microbiol; 2016; 59(1):41-6. PubMed ID: 26960633
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinicopathological features of aggressive B-cell lymphomas including B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell and Burkitt lymphomas: a study of 44 patients from Argentina.
    Bürgesser MV; Gualco G; Diller A; Natkunam Y; Bacchi CE
    Ann Diagn Pathol; 2013 Jun; 17(3):250-5. PubMed ID: 23246412
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Triple-hit B-cell Lymphoma With MYC, BCL2, and BCL6 Translocations/Rearrangements: Clinicopathologic Features of 11 Cases.
    Wang W; Hu S; Lu X; Young KH; Medeiros LJ
    Am J Surg Pathol; 2015 Aug; 39(8):1132-9. PubMed ID: 25828391
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aggressive B-cell lymphomas with translocations involving BCL6 and MYC have distinct clinical-pathologic characteristics.
    Turakhia SK; Hill BT; Dufresne SD; Nakashima MO; Cotta CV
    Am J Clin Pathol; 2014 Sep; 142(3):339-46. PubMed ID: 25125624
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas.
    Pillai RK; Sathanoori M; Van Oss SB; Swerdlow SH
    Am J Surg Pathol; 2013 Mar; 37(3):323-32. PubMed ID: 23348205
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Diagnostic Approach to the Identification of Burkitt-like Lymphoma With 11q Aberration in Aggressive B-Cell Lymphomas.
    Horn H; Kalmbach S; Wagener R; Staiger AM; Hüttl K; Mottok A; Bens S; Traverse-Glehen A; Fontaine J; Siebert R; Rosenwald A; Ott G
    Am J Surg Pathol; 2021 Mar; 45(3):356-364. PubMed ID: 33136583
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival.
    Johnson NA; Savage KJ; Ludkovski O; Ben-Neriah S; Woods R; Steidl C; Dyer MJ; Siebert R; Kuruvilla J; Klasa R; Connors JM; Gascoyne RD; Horsman DE
    Blood; 2009 Sep; 114(11):2273-9. PubMed ID: 19597184
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinicopathologic findings in high-grade B-cell lymphomas with typical Burkitt morphologic features but lacking the MYC translocation.
    Sevilla DW; Gong JZ; Goodman BK; Buckley PJ; Rosoff P; Gockerman JP; Lagoo AS
    Am J Clin Pathol; 2007 Dec; 128(6):981-91. PubMed ID: 18024324
    [TBL] [Abstract][Full Text] [Related]  

  • 32. C-MYC overexpression predicts aggressive transformation and a poor outcome in mucosa-associated lymphoid tissue lymphomas.
    Huang W; Guo L; Liu H; Zheng B; Ying J; Lv N
    Int J Clin Exp Pathol; 2014; 7(9):5634-44. PubMed ID: 25337204
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis.
    Kanungo A; Medeiros LJ; Abruzzo LV; Lin P
    Mod Pathol; 2006 Jan; 19(1):25-33. PubMed ID: 16258503
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Expression of dendritic cell marker CD21 is a positive prognostic factor in diffuse large B-cell lymphoma].
    Yao WK; Wang YP; Peng F; Zheng Y; Zou YB; Gao JN; Liu XL
    Zhonghua Bing Li Xue Za Zhi; 2012 Dec; 41(12):818-22. PubMed ID: 23324230
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Primary gastrointestinal diffuse large B-cell lymphoma: an immunohistochemical and prognostic study of 90 cases].
    Lin L; Min M; Bi CF; Wang XQ; Luo TY; Zhao S; Zhang WY; Liu WP
    Zhonghua Bing Li Xue Za Zhi; 2011 Apr; 40(4):220-6. PubMed ID: 21615994
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical characteristics and prognosis of concurrent positive t(14; 18) and myc gene rearrangement in diffuse large B cell lymphoma].
    Zhang HW; Chen ZW; Wang LY; He JX; Zheng YP; Han WE; Yang B; Wang YL; Zhao ZQ; Bai M; Su LP
    Zhonghua Zhong Liu Za Zhi; 2016 Mar; 38(3):206-10. PubMed ID: 26988827
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Impact of PRDM1 gene inactivation on C-MYC regulation in diffuse large B-cell lymphoma].
    Zhang XY; Ma ZP; Cui WL; Pang XL; Chen R; Wang L; Zhang W; Li XX
    Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):25-31. PubMed ID: 29325247
    [No Abstract]   [Full Text] [Related]  

  • 38. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
    Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
    J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
    [TBL] [Abstract][Full Text] [Related]  

  • 39. T-cell leukemia 1 expression in nodal Epstein-Barr virus-negative diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma.
    Gualco G; Weiss LM; Barber GN; Bacchi CE
    Hum Pathol; 2010 Sep; 41(9):1238-44. PubMed ID: 20382409
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characteristics of CD5-positive diffuse large B-cell lymphoma among Koreans: High incidence of BCL2 and MYC double-expressors.
    Na HY; Choe JY; Shin SA; Kim HJ; Han JH; Kim HK; Oh SH; Kim JE
    PLoS One; 2019; 14(10):e0224247. PubMed ID: 31644584
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.